BodyHealth
Gut Restore
Gut Restore
无法加载取货服务可用情况
Product Overview
Gut Restore is a capsule-form dietary supplement manufactured by BodyHealth, LLC (Florida, USA) and supplied in Singapore by Essential Medical International Supplies (emis.asia) for adult populations seeking targeted gastrointestinal mucosal support. The formulation is built around three evidence-anchored constituents: ImmunoLin® (a serum-derived bovine immunoglobulin/protein isolate, SBI), humic acid (a poly-mineral organic acid extract supporting tight-junction integrity), and PerfectAmino® (a 1–3 BCAA-balanced essential amino acid matrix). Together these are formulated to bind a broad range of luminal antigens, deliver substrate amino acids for enterocyte turnover, and supply bioavailable trace minerals.
The product is indicated as adjunctive nutritional support and is not a treatment for diagnosed gastrointestinal disease. Manufacturing is performed in a US FDA-registered facility under 21 CFR Part 111 current Good Manufacturing Practice (cGMP) for dietary supplements. The finished product is non-allergenic, free of sugar, gluten, dairy, soy, MSG, and artificial sweeteners.
Specifications
| Manufacturer | BodyHealth, LLC (Tampa, FL, USA) |
|---|---|
| Product Format | Vegetarian capsule, oral dietary supplement |
| Key Actives | ImmunoLin® serum-derived bovine immunoglobulins (SBI); Humic acid; PerfectAmino® essential amino acid complex |
| Allergen Profile | Free of gluten, dairy, soy, MSG, added sugar, artificial sweeteners |
| Manufacturing Standard | Manufactured in a US FDA-registered facility under 21 CFR Part 111 cGMP for dietary supplements |
| Quality Reference | ImmunoLin® ingredient is GRAS-affirmed (FDA GRN No. 429) and produced under ISO 9001-aligned quality systems |
| Regulatory Status (Singapore) | Notified as a health supplement under the Health Sciences Authority (HSA) Health Products Act framework. Not a registered therapeutic product; not for the diagnosis, cure, or treatment of disease. |
| Storage | Store below 25°C in a dry environment, away from direct sunlight |
| Suitability | Adults; consult a healthcare professional before use during pregnancy, lactation, or with concurrent immunosuppressive therapy |
Clinical Indications & Use Cases
- Adjunctive nutritional support in adults with irritable bowel syndrome - diarrhoea predominant (IBS-D) seeking luminal antigen binding (Wilson et al., Clin Exp Gastroenterol 2013)
- Mucosal barrier support following broad-spectrum antibiotic exposure or chemotherapy-induced dysbiosis
- Adjunct to elimination protocols in patients with non-coeliac food sensitivities under dietitian supervision
- Adults with chronic non-specific bloating, postprandial discomfort, or low-grade systemic inflammation referenced to intestinal permeability
- Endurance athletes managing exercise-induced gastrointestinal permeability and immune dysregulation
- Older adults (≥60) supporting age-related decline in mucosal IgA and microbial diversity
Frequently Asked Questions
Q: Why is ImmunoLin® (serum-derived bovine immunoglobulin) preferred over generic colostrum?
A: Standard colostrum delivers a variable IgG load and a high lactose/fat fraction. ImmunoLin® is a concentrated SBI isolate with >50% protein as immunoglobulin and a defined IgG content per gram, allowing reproducible dosing. Randomised controlled data in IBS-D (Wilson 2013) used 5–10 g/day of SBI; capsule formulations provide a maintenance dose for general mucosal support.
Q: Is this product appropriate for patients with diagnosed inflammatory bowel disease (IBD)?
A: Patients with confirmed Crohn disease or ulcerative colitis should not self-medicate. Initiation should be discussed with the treating gastroenterologist, particularly where biologic, JAK-inhibitor, or corticosteroid therapy is concurrent. The product is a nutraceutical and does not replace disease-modifying therapy.
Q: How long should the supplement be taken before assessing benefit?
A: Published SBI trials report symptomatic change over 6–8 weeks. A minimum 8-week trial at the labelled dose is reasonable before reassessing with the clinician. Symptom diaries and validated tools (IBS-SSS, Bristol Stool Form Scale) support objective evaluation.
Q: What regulatory framework applies to this supplement in Singapore?
A: In Singapore, dietary supplements are classified under the HSA Health Products Act as health supplements rather than therapeutic products. They are not subject to pre-market HSA registration but must comply with labelling requirements, prohibited-substance lists, and post-market surveillance. emis.asia retains supplier Certificates of Analysis and lot traceability documentation.
Q: Are there interactions with prescription medication?
A: SBI products bind luminal proteins and may theoretically delay absorption of orally administered drugs. Best practice is to separate the supplement from oral medications by at least 2 hours. Discuss use with a pharmacist if on narrow-therapeutic-index drugs (eg, levothyroxine, ciclosporin, warfarin).
分享
